Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Kowa Co., Ltd. engages in trading of textiles, machinery, and construction materials. The company also manufactures and sells medicines, medical equipment, and energy saving products. It operates through the following business divisions: Pharmaceutical, Medical Device, Foods, General Trading, Lifestyle Business, and Hospitality. The company was founded on December 25, 1894 and is headquartered in Nagoya, Japan.

Proyecto de Biomedicina CIMA SL is a holding company engaged in the provision of product licensing and intellectual property rights management services. It holds patents generated by the Centro de Investigacion Medica Aplicada, which have indications across the clinical fields of oncology, hepatology, dermatology, and gene therapy. The company was founded in June 2003 and is headquartered in Pamplona, Spain.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

ISARIC - International Severe Acute Respiratory and Emerging Infection Consortium - is a global initiative aiming to ensure that clinical researchers have the open access protocols and data-sharing processes needed to facilitate a rapid response to emerging diseases that may turn into epidemics or pandemics.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Kansai Technology Licensing Organization Co. Ltd. is a Japanese private company that provides technology transfer and research exchange services around the world.

Beijing Kuangbo Biotechnology Co., Ltd., established on 2009-08-12, Business scope includes technology development of biotechnology,technical consulting,Technology Exchange,Technology Promotion,technology transfer,Technical Services,Technical Training;Import and export,Technology Import and Export,Agent import and export;Conference Services;Exhibition display service;Sales of biological reagents,Reagent test kit(Except for projects subject to special approval),Instrumentation,Class I,Class II medical device;production of biological reagents,Reagent test kit(Except for projects subject to special approval);Sales of Class III medical devices.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Part of Eisai Co., Ltd., EA Pharma Co., Ltd. is a company headquartered in Tokyo, Japan, that manufactures pharmaceutical products for gastrointestinal disease.

Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

Jiangsu Xianstar Biotechnology Co., Ltd., established on 2014-12-10, Business scope includes biotechnology research and development,Medical device research and development,Production,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Technology Import and Export;Import and export;Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Specialty Chemicals Sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Zhejiang Puli Pharmaceutical Co., Ltd., established on 2003-08-13, Business scope includes licensed projects:Drug Wholesale;Drug retail;pharmaceutical production;Production of Class II Medical Devices;food production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Import and export;Pharmaceutical special equipment sales;Machinery sales;Metal Material Sales;food sales(Only sell prepackaged food);Chemical product sales(No licensed chemical products);Sales of electronic components and electromechanical components;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Hainan Poly Pharm. Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The firm is specialized in injections and oral solid formulations. Its products include injection, oral solid dosage, dry suspension and active pharmaceutical ingredient (API). The company was founded by Min Hua Fan on July 14, 1992 and is headquartered in Haikou, China.

Hangzhou Saili Pharmaceutical Research Institute Co., Ltd., established on 2000-04-20, Business scope includes technology development,Serve,Achievement transfer:drug,Chemical raw materials,medical instruments,chemical reagent,diagnostic test strips;Serve:Economic Information Consulting(In addition to commodity intermediary)

Umecrine Cognition develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids (GABA steroids). Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus the development activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids). The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease.

Shenzhen Gedaosu Biotechnology Co., Ltd., established on 2019-10-10, Business scope includes general business items:Glycobiotechnology research,to develop,Technical Services,technology transfer;Operating import and export business,The licensing program is:Production of kits,Sales;Production of biological reagents,operate

PROPRIUM creates biomedical products and diagnostic techniques intended to serve the biotech field. The company has diagnostic techniques to detect carcinoma, liver, cardiovascular, and cerebrovascular diseases. They offer cancer diagnostics, genetic testing, elisa, lateral flow assays, and personalized medicine.

CAR-T (Shanghai) Biotech Co., Ltd. engages in the research and development bioengineering, medical, stem cells, and healthcare services. Its business scope includes manufacture of medical devices, hygiene supplies, and disposable medical supplies; and technical development, services, consulting, and technology transfer of therapeutic technology, biotechnology, laboratory equipment technology, and cosmetics technology. The company was founded on December 31, 2015 and is headquartered in Shanghai, China.